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The feline infectious peritonitis virus (FIPV) is a member of the feline coronavirus family that causes FIP, which is
incurable and fatal in cats. Cyclosporin A (CsA), an immunosuppressive agent that targets the nuclear factor
pathway of activated T-cells (NF-AT) to bind cellular cyclophilins (CyP), dose-dependently inhibited FIPV replication
in vitro. FK506 (an immunosuppressor of the pathway that binds cellular FK506-binding protein (FKBP) but not CyP)
did not affect FIPV replication. Neither cell growth nor viability changed in the presence of either CsA or FK506, and
these factors did not affect the NF-AT pathway in fcwf-4 cells. Therefore, CsA does not seem to exert inhibitory
effects via the NF-AT pathway. In conclusion, CsA inhibited FIPV replication in vitro and further studies are needed
to verify the practical value of CsA as an anti-FIPV treatment in vivo.Introduction
Coronaviruses are single-stranded RNA viruses that gener-
ally cause respiratory or intestinal infections such as severe
acute respiratory syndrome (SARS) in humans and trans-
missible gastroenteritis (TGE) in pigs. Feline coronaviruses
(FCoV) have been classified into two biotypes, comprising
the ubiquitous feline enteric coronavirus (FECV) and infec-
tious peritonitis virus (FIPV). The widely accepted theory
in vitro is that FIPV arises by mutation of parental FECV in
the gastrointestinal tract of infected cats, then systemically
spreads and causes FIP that is fatal in cats [1,2]. Although
the mutation sites are not fully understood, some accessory
genes are candidates for the site of the critical mutations
responsible for FIP [3,4]. Approximately 80 % of all pure-
bred cats are infected with feline coronavirus and among
these, 5-12 % develop the classical symptoms of effusive/
wet FIP, the non-effusive/dry form of FIP, or a combination
of the two [5].
Many strategies have been developed to cure FIP. Inter-
feron ω inhibits FIPV in vitro but is ineffective in vivo [6].
Various other immunosuppressants, such as glucocorticoids
and cyclophosphamide, have been studied, but although
these drugs prolong life, the outcome of FIPV infection
remains fatal [7]. Thus, an effective vaccine and therapeutic
medicine against FIPV are still needed.* Correspondence: ytanaka@nvlu.ac.jp
1Department of Veterinary Hygiene, Veterinary School, Nippon Veterinary and
Life Science University, 1-7-1 Kyounan, Musashino, Tokyo, 180-8602, Japan
Full list of author information is available at the end of the article
© 2012 Tanaka et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orInvestigators have reported that the immunosuppressant
cyclosporin A (CsA) can suppress the genomic replication
and transcription of several viruses [8-11]. Cyclophilins
(CyP) are cellular factors with high affinity for CsA [12]
and comprise a family of cellular peptidyl-prolyl cis-trans
isomerases (PPIases) that catalyze the cis-trans interconver-
sion of the amino-terminal of peptide bonds to proline resi-
dues, thus facilitating changes in protein conformation as a
chaperone protein [13]. Cyclosporin A blocks both the en-
zymatic activities of CyP that lead to the calcineurin (CN)-
NF-AT and P-glycoprotein pathways. The capsid protein of
human immunodeficiency virus type 1 (HIV-1) possesses a
cyclophilin A (CyPA) binding site for incorporation into
the virion [14,15]. A CsA-induced reduction in CyPA inhi-
bits transport of the reverse-transcribed viral genome to
the nucleus [16]. Cyclophilin B (CyPB) is another target of
CsA that promotes hepatitis C virus (HCV) replication
by regulating the RNA-binding ability of the HCV NS5B
protein. In addition, CyPA facilitates mouse cytomegalo-
virus (MCMV) replication and CyPB is required for the in-
fectious entry of human papillomavirus type 16.
Here, we show that CsA inhibits intracellular replica-
tion of the FIPV genome and viral protein expression
in vitro independently of the NF-AT pathway.
Materials and methods
Cell culture and virus
Felis catus whole fetus-4 (fcwf-4; American Type Culture
Collection, VA, USA) cells were maintained in Dulbecco’sLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Japan) supplemented with 10 % fetal bovine serum (JRH,
Nissui, Tokyo, Japan). We propagated FIPV (79-1146
strain; a gift from Dr Tsutomu Hodatsu, Kitasato Univer-
sity, Japan) in fcwf-4 cells and then purified them by linear
sucrose gradient ultracentrifugation.
Cells treated with cyclosporin A, cyclosporin H, and FK506
We inoculated fcwf-4 cells with FIPV 79–1146 at a multi-
plicity of infection (MOI) of 1 plaque-forming unit (pfu)
per cell to study their effects on FIPV infection. After ad-
sorption for 1 h at 37°C, the medium containing the virus
was removed, and the cells were rinsed three times with
phosphate-buffered saline [PBS (−)] and incubated with or
without various concentrations of CsA (Sigma-Aldrich),
cyclosporin H (CsH; Cosmobio, Tokyo, Japan) and FK506
(Sigma-Aldrich) for 20 h. The cells were then processed
for photography. The cells were adsorbed with FIPV,
rinsed three times with PBS (−), overlaid with DMEM con-
taining 5 % fetal bovine serum and 2 % Agarose S (Nippon
Gene, Toyama, Japan). After a 20-h incubation, the cells
were stained with Giemsa solution and the plaques were
counted.
Plasmid constructs
We isolated the nucleocapsid (N) gene of FIPV from the
plasmid pBRDI1 (provided by Dr Peter J. M. Rottier, Insti-
tute of Biomembranes, Utrecht University, The Netherlands)
containing the FIPV 79–1146 genome, using the polymerase
chain reaction (PCR) with the primers 5’-ACAAGGAC
GACGACGACAAGGCCACACAGGGACAACGCG-3’ and
5’-CCGGAATTCTTAGTTCGTAACCTCATCAA-3’ for the
first amplification. The products of the first amplification
were purified by electrophoresis and gel extraction, and
then a second PCR proceeded with the purified products
and primers containing a FLAG-tagged sequence: (5’-
GCCACCATGGACTACAAGGACGACGACGACAAG-3’
and 5’-CCGGAATTCTTAGTTCGTAACCTCATCAA-3’).
The second PCR products were cut with Nco I and Eco RI
and subcloned into the sites between Nco I and Eco RI of
the pTri-EX 1.1 vector (Novagen, Takara Bio, Kyoto,
Japan) to express FLAG-tagged N protein.
Real-time, quantitative reverse transcription-PCR
(qRT-PCR)
The fcwf-4 cells were infected at an MOI of 1 pfu per cell
and then incubated with or without CsA, CsH or FK506.
The medium was removed at 22 h post-infection, and
RNAiso-plus (Takara Bio) was added to the cells for RNA
preparation according to the manufacturer’s protocol.
Total RNA (800 ng) was reverse-transcribed using the Pri-
meScript RT-PCR kit (Perfect Real Time; Takara Bio).
Viral cDNA were quantified by real-time PCR using
the forward and reverse primers to the FIPV-N gene(5’-TGGCCACACAGGGACAAC-3’) and (5’-AGAAC
GACCACGTCTTTTGGAA-3’), and the TaqMan probe
(FAM-GTTGCA GCACAGCCAGCATAAACAA-BHQ-1).
Reaction mixtures were prepared according to the manu-
facturer’s protocol using Premix EXTaq (Takara Bio), and
sequences were amplified using a 7500 Sequence Detec-
tion System (Applied Biosystems, Tokyo, Japan) under the
following cycling conditions: initial denaturation at 95°C
for 10 s and 40 cycles at 95°C for 5 s and 60°C for 36 s
each. Complementary DNA to the FIPV-N gene was
cloned into the pTri-EX 1.1 vector, which was serially
diluted to provide standards for FIPV gene quantifica-
tion. The viral RNA copy number was normalized using
the feline β-2-microglobulin (β2M) gene (GenBank;
NM_001009876). The β2M gene derived from fcwf-4
cells was cloned by PCR amplification using the following
primers: fβ2M-F 5’-GGCGCGTTTTGTGGTCTTGGTC-
3’ and fβ2M-R 5’-CACTTAACGACCTTGGGCTC-3’. The
amplified PCR products were subcloned into pTAC-1
plasmids (BioDynamics Laboratory Inc. Tokyo, Japan)
to provide standards for the β2M gene. We then quanti-
fied the feline β2M gene by real-time PCR using the for-
ward (5’-CGCGTTTTGTGGTCTTGGTCTTGGT-3’) and
reverse (5’-AAACCTGAACCTTTGGAGAATGC-3’) pri-




Luciferase activities were quantified using pGL4.30
[luc2P/NFAT-RE/Hygro] (Promega, Tokyo, Japan),
pRL-SV40 vectors for the NF-AT response assay and
the interferon stimulation response was determined
using the plasmid pISRE-TK hRluc (F) provided by
RIKEN BioResource Center (Tsukuba, Japan) and the
pGL3 promoter (Promega). Both reporter assays pro-
ceeded using the Dual-Luciferase Reporter Assay Sys-
tem (Promega). Briefly, the two reporter plasmids were
co-transfected into fcwf-4 cells with or without CsA or
FK506 for each assay. Recombinant feline IFNα (PBL
Biomedical Laboratories, NJ, USA) was added at a con-
centration of 10 units/mL to the culture medium to
evaluate the response to interferon (IFN). Total cell
lysates were prepared with Reporter Lysis buffer pro-
vided with the Dual-Luciferase Reporter Assay System
at 48 h before the assay. Luciferase activities were
quantified in triplicate assays using a Lumat LB9507
(Berthold Technologies, Tokyo, Japan).
Western blotting
The cell membranes were disrupted with cell lysis buffer
[10 mM Tris–HCl, pH 7.8, 1 mM ethylenediamine tetra-
acetic acid (EDTA), 1 % NP-40, 0.15 M NaCl] including















































Figure 1 Cyclosporin A inhibits cytopathic effects of FIPV on fcwf-4 cells. (A) WST-8 assay of fcwf-4 cells cultured with indicated
concentrations of CsA. Error bars indicate means ± 2SD. *P, **P< 0.05. (B) Plaques counted in FIPV-infected fcwf-4 cells incubated with or without
CsA. Cells infected with FIPV were incubated with various concentrations of CsA.
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electrophoresis on 4-12 % Bis-Tris gels (Invitrogen, CA,
USA) and Western blotted onto Immobilon-P mem-
branes (Millipore, Tokyo, Japan). Non-specific protein
binding was blocked with 5 % non-fat dry milk for 1 h
and then the membranes were incubated with anti-feline
coronavirus nucleocapsid (N) antibody (FIPV3-70;
MyBioSource, CA, USA) or anti-β-actin (Sigma-Aldrich)
for 1 h. Antigen signals were visualized by reacting pro-
teins on the membranes with horseradish peroxidase-
conjugated anti-mouse IgG antibody (Promega) fol-
lowed by an enhanced chemiluminescence substrate
(SuperSignal West Femto Maximum SensitivitySubstrate; Thermo Scientific, Tokyo, Japan) according
to the manufacturer’s protocol.
Cell viability assay
We assayed WST-8 to evaluate cytotoxicity using the
Cell Counting Kit-8 (Dojin Chemical Inc., Wako, Japan)
according to the manufacturer’s directions.
Statistical analysis
Statistical significance was determined using the Student’s t
test. For all data analyzed, a significance threshold
of P< 0.05 was assumed. The values are expressed in some
figures as means± standard deviation (SD).
Figure 2 FK506 does not inhibit cytopathic effects of FIPV on
fcwf-4 cells. (A) WST-8 assay of fcwf-4 cells cultured with various
FK506 concentrations. Error bars indicate means ± 2SD. *P< 0.05. (B)
The numbers of plaque were counted in FIPV-infected fcwf-4 cells
incubated with or without FK506. Cells infected with FIPV were
cultured with various concentrations of FK506.
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Inhibition of FIPV replication by CsA but not by FK506
We initially assessed the effects of CsA on FIPV RNA
replication using cytotoxicity assays. Cyclosporin A at
concentrations of 0–6.3 μM (cytotoxic dose50,
14.1±1.72 μM) did not affect fcwf-4 cell viability (Figure 1A)
and dose-dependently reduced the numbers of FIPV
plaques (Figure 1B), whereas 10 μM CsA was slightly
cytotoxic. Cyclosporin A blocks both the enzymatic
activities of CyP that lead to the calcineurin (CN)-NF-
AT and the P-glycoprotein pathway. We therefore
assessed the effect of various concentrations of FK506,
which also blocks the NF-AT pathway, on cell viability
to confirm that CsA inhibited FIPV through this path-
way. The cytopathic inhibitory effects did not signifi-
cantly differ in the presence or absence of 0.08 - 10 μM
FK506 (Figure 2B) and cell viability was not affected by
10 μM FK506 (Figure 2A).
Quantitative RT-PCR showed that 0.63 - 10 μM CsA
dose-dependently suppressed FIPV RNA replication,
whereas FK506 did not exert significant inhibitory
effects, except at 10 μM FK506 (approximately 30 %reduction compared to 0 μM FK506, P< 0.05; Figure 3A).
Western blotting showed that CsA, but not FK506 dose-
dependently decreased FIPV-N protein (Figure 3B).
We then examined whether the suppressive effects of
CsA on FIPV replication depend on the inhibitory NF-
AT pathway or P-glycoprotein pathway by incubating
FIPV-infected cells with CsH, which specifically blocks
the P-glycoprotein pathway. The results show that no in-
hibition occurred (data not shown).
CsA does not elicit either an interferon-stimulated
response or a NF-AT response in fcwf-4 cells
To determine whether the action of CsA and FK506
involves activation of interferon-stimulated gene responses
in fcwf-4 cells, the ISRE-luciferase reporter plasmid, pISRE-
TK hRluc (F) and pGL3 promoter plasmid as a
normalization-control plasmid were transfected into fcwf-4
cells and cultured with feline interferon α, CsA or FK506.
The results of the dual-luciferase assay showed that none
of these factors significantly affected luciferase activities at
48 h after transfection. These results indicate that fcwf-4
cells are unresponsive, even to interferon α (Figure 4A).
Consequently, the action of CsA on intracellular FIPV
replication does not involve the activation of interferon-
stimulated genes on fcwf-4 cells. Moreover, to evaluate the
effects of CsA and FK506 on the calcineurin-NF-AT path-
way in fcwf-4 cells, the NF-AT luciferase reporter plasmid,
pGL4.30 [luc2P/NFAT-RE/Hygro] and pRL-SV40 as a
normalization-control plasmid were transfected into fcwf-
4 cells that had been incubated with CsA or FK506. Nei-
ther CsA nor FK506 affected NF-AT luciferase activities in
fcwf-4 cells (Figure 4B). These findings show that CsA
does not influence the NF-AT pathway in fcwf-4 cells and
that the inhibition of FIPV RNA replication by CsA is in-
dependent of the calcineurin NF-AT pathway.
Discussion
We discovered that CsA inhibits intracellular FIPV repli-
cation in vitro. The results of qRT-PCR and Western
blotting showed that viral proliferation was strikingly
inhibited at CsA concentrations between 0.16 and
10 μM. The results of cell viability assays showed that
10 μM CsA was slightly cytotoxic. The inhibitory effects
at this concentration should therefore be considered in
the light of cytotoxicity. In contrast, immunosuppressive
FK506 did not inhibit FIPV replication except at 10 μM
according to the qRT-PCR findings. However, the inhibi-
tory effects of 0.08 - 10 μM FK506 did not significantly
differ on Western blots and the number of plaques did
not significantly differ within the same concentration
range of FK506. These findings might be related to the
difference of the analytical detection sensitivity between
qRT-PCR and Western blot assays. Cyclosporin A binds
cyclophilins, whereas FK506 binds cellular FKBP. Each
Figure 3 Cyclosporin A, but not FK506 suppresses FIPV replication in fcwf-4 cells. (A) Cells were infected with FIPV and incubated with or
without the indicated concentrations of CsA or FK506. Total RNA extracted from cells 22 h later were reverse-transcribed to cDNA and assayed by
real-time PCR assays targeting FIPV-N and β2M genes. Relative amounts of FIPV RNA expression data were normalized with β2M gene expression.
Error bars indicate means ± 2SD. (B) Western blots of cells incubated with various concentrations of CsA and FK506. Lanes show total cellular
proteins resolved by electrophoresis. Effects of CsA and FK506 were assessed using monoclonal anti-FIPV-N and anti-β-actin primary antibodies.
Tanaka et al. Veterinary Research 2012, 43:41 Page 5 of 7
http://www.veterinaryresearch.org/content/43/1/41complex independently inhibits the phosphatase activity of
calcineurin that mediates the NF-AT pathway, which is
critical to the expression of cytokines and their receptors
[12,17]. The results of NF-AT reporter assays indicate that
neither CsA nor FK506 influenced NF-AT activities on
fcwf-4 cells under our experimental conditions. Thus, the
antiviral activity against FIPV is not involved in the sup-
pression of gene responses regulated by NF-AT but instead
is exerted through distinct mechanisms that are independ-
ent of FK506. Pfefferle et al. recently described that SARS-
coronavirus NSP1 overexpression increases signaling
through the NF-AT pathway and enhances the induction
of interleukin 2 [18]. Our data were somewhat inconsistent
with these findings. The discrepancy might be explained in
part by the fact that their experimental system included
the addition of 13-O-Acetylphorbol 12-myristate (PMA)
and ionomycin to the culture medium. Further knock-
down studies of the NF-AT gene would clarify its role in
FIPV proliferation. Furthermore, IFNα did not stimulate
ISRE-promoter activities in fcwf-4 cells under these condi-
tions. These data suggest that the action of CsA on theintracellular replication of FIPV is independent of the IFN
pathway. This cell line might not be responsive to IFNα
and would thus be useful for isolating feline coronavirus.
Cyclophilins have PPIase activity [13,19-21], contribute
to the maturation of several proteins, and are involved in
cell signaling, mitochondrial function (ATP synthesis),
molecular chaperone activity, RNA splicing, stress re-
sponse, gene expression, cholesterol transport, and the
regulation of kinase activity [22-25]. Surface plasmon
resonance technology and bioinformatics tools have
found that the SARS coronavirus N protein binds to
CyPA [26-28]. Therefore, the N protein of FIPV probably
binds to CyP proteins to regulate viral replication. The
roles of CyP in virus replication and the inhibitory effect
by CsA on HCV and several other viruses have been
studied [22-25]. The proposed mechanisms of the inhibi-
tory effect of CsA mainly involve CypA and CypB in
virus replication [23,29,30]. Based on these earlier find-
ings, we believe that interaction between the FIPV gen-
ome is likely or that viral and CyP proteins play critical
roles in viral replication and transcription. Further
Figure 4 CsA does not affect interferon-stimulated gene responses and NF-AT activities. (A) Control vector pGL3 plasmid for normalization
and ISRE-luciferase plasmid were transfected into fcwf-4 cells which were then incubated with or without indicated concentrations of CsA and
FK506. Culture medium also contained interferon α (10 U/mL). Dual luciferase activities were measured at 48 h after transfection. (B) Plasmid
vectors pGL4.30 [luc2P/NFAT-RE/Hygro] and pRL-SV40 for NF-AT response assays were transfected into fcwf-4 cells that were then cultured with or
without indicated concentrations of CsA and FK506. Dual luciferase activities were measured at 48 h after transfection. Transfection efficiency was
normalized by Renilla luciferase gene expression.
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viral replication and which viral protein is required to
form replication complexes with CyP and/or other cellu-
lar proteins.
Cats with clinically diagnosed FIP have very rarely been
cured, although several therapeutic strategies have been
attempted. Some cats treated with prednisolone and
phenylalanine mustard or cyclophosphamide have gone
into remission [26]. Various immunosuppressants, such as
glucocorticoids and cyclophosphamide, may prolong life
but do not alter the fatal outcome [4].
Further investigations using PPIase dominant-negative
assays and RNA interference methods are warranted to
clarify the role of CsA against PPIase in FIPV replication
in vitro. In addition, whether CsA could be useful as FIP
treatment in vivo remains to be determined
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